Showing results (41-50 of 56) with videos related to
Sort By:
Pageof 6
Cancer Research|March 22, 2018
Autocrine Adenosine Regulates Tumor Polyfunctional CD73<sup>+</sup>CD4<sup>+</sup> Effector T Cells Devoid of Immune CheckpointsNicolas Gourdin, Marion Bossennec, Céline Rodriguez, et al.Oncoimmunology|June 28, 2024
Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patientsStéphane Dalle, Estelle Verronese, Axelle N'Kodia, et al.Therapeutic Advances in Medical Oncology|August 11, 2025
Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacyOlivia Le Saux, Renaud Sabatier, Isabelle Treilleux, et al.Science Immunology|April 19, 2020
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancerMargaux Hubert, Elisa Gobbini, Coline Couillault, et al.Journal for Immunotherapy of Cancer|June 18, 2026
Melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapyFélix K Pham, Marion Dufeu, Valentin Benboubker, et al.Journal for Immunotherapy of Cancer|March 15, 2022
ZEB1 transcription factor promotes immune escape in melanomaMaud Plaschka, Valentin Benboubker, Maxime Grimont, et al.Breast Cancer (Dove Medical Press)|May 4, 2023
Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective StudyBenoîte Mery, Christine Ménétrier-Caux, Laure Montané, et al.Acta Neuropathologica|January 5, 2018
Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degenerationMathilde Small, Isabelle Treilleux, Coline Couillault, et al.Cancer Immunology Research|January 8, 2025
The Spatial Organization of cDC1 with CD8+ T Cells is Critical for the Response to Immune Checkpoint Inhibitors in Patients with MelanomaElisa Gobbini, Margaux Hubert, Anne-Claire Doffin, et al.Science Translational Medicine|January 24, 2024
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancersAurélien Voissière, Carlos Gomez-Roca, Sylvie Chabaud, et al.Pageof 6